Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Closed 05-12 16:00:00 EDT

71.81

+1.07

+1.52%

High72.24	Low70.73	Vol741.39M
Open70.74	D1 Closing70.74	Amplitude2.14%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O16.30B	T/O Rate--	Tradable Shares0.00
P/B6.800817	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":71.81176,"timestamp":1778615999999,"preClose":70.7371,"halted":0,"volume":741389894,"delay":0,"changeRate":0.015192,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":1.074661,"latestTime":"05-12 16:00:00 EDT","open":70.73718,"high":72.24438,"low":70.73166,"amount":16296066494.746607,"amplitude":0.021385,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778630400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.800817,"peRate":-163.871793,"turnoverRate":0.02263,"increases":215,"decrements":282,"flats":15,"marketCap":1851958704277.6875,"floatMarketCap":1654682531951.084},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2635022612","title":"Gyre Therapeutics announces China NMPA acceptance of F351 NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635022612","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635022612?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:36","pubTimestamp":1778625416,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation, or CDE, of China’s National Medical Products Administration, or NMPA, has a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-china-nmpa-acceptance-of-f351-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-china-nmpa-acceptance-of-f351-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226463","title":"Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226463?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:31","pubTimestamp":1778625086,"startTime":"0","endTime":"0","summary":"The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the en...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-reports-q1-net-loss-12-7m-vs-6-8m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-reports-q1-net-loss-12-7m-vs-6-8m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226626","title":"BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226626?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:30","pubTimestamp":1778625003,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryBridgeBio Oncology Therapeutics Inc BBOT.OQ reported a quarterly adjusted loss of 53 cents per shar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P3BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BBIO","BK4588","BK4139","BBOT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635261712","title":"Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635261712","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635261712?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:28","pubTimestamp":1778624902,"startTime":"0","endTime":"0","summary":"Sana Biotechnology (SANA) announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achie...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","SANA","BK4139","CAR","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226504","title":"RA Capital Management disposes 565,167 Werewolf Therapeutics shares worth $389,277","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226504","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226504?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:27","pubTimestamp":1778624829,"startTime":"0","endTime":"0","summary":"RA Capital Management, a 10% owner of Werewolf Therapeutics , reported sales of common stock on May 8, May 11, and May 12.RA Capital Healthcare Fund sold 527,624 shares at weighted-average prices of $0.71, $0.67, and $0.64, cutting its stake to 5,709,858 shares.Nexus Fund II sold 37,543 shares at the same weighted-average prices, reducing its holding to 406,282 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL82sQlK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"RA Capital Management disposes 565,167 Werewolf Therapeutics shares worth $389,277","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOWL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635338226","title":"Sellas Life Sciences Shares Climb as Trial Nears Data Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2635338226","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635338226?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:17","pubTimestamp":1778624220,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences shares rose after the company said its Phase 3 trial is nearly ready for data review.The stock gained 13% to $5.91 in after-hours trading. Through the close, the stock was up 38% year to date.The late-stage clinical biopharmaceutical company's Phase 3 trial evaluating Galinpepimut-S as a treatment for leukemia requires 80 pre-specified events to lock the database and start analyzing it.As of May 11, 78 events had occurred, Sellas said. The company plans to provide an update when the 80th event happens.Sellas also said its loss widened to $8.4 million, or 5 cents a share, compared with a loss of $5.8 million, or 7 cents a share, in the year-ago quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226539","title":"Immunome reports Q1 EPS (48c), consensus (54c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226539","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226539?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:13","pubTimestamp":1778624005,"startTime":"0","endTime":"0","summary":"“This quarter reflects the progress we are making in building Immunome (IMNM) into a multi-program targeted oncology company,” said Clay B. Siegall...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-reports-q1-eps-48c-consensus-54c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-reports-q1-eps-48c-consensus-54c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","IMNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635584226","title":"Mirum Pharmaceuticals announces $600M convertible senior notes offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2635584226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635584226?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:09","pubTimestamp":1778623768,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals (MIRM) announced its intention to offer, subject to market conditions and other factors, $600M aggregate principal amount of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-announces-600m-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-announces-600m-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635257072","title":"Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635257072","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635257072?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:08","pubTimestamp":1778623728,"startTime":"0","endTime":"0","summary":"May 12 (Reuters) - BridgeBio Oncology Therapeutics Inc ::*BBOT REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS*BRIDGEBIO ONCOLOGY THERAPEUTICS INC: CASH RUNWAY EXPECTED T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nRSD8qKHxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226553","title":"Curis sees cash and proceeds enough for operations into second half of FY27","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226553?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:07","pubTimestamp":1778623621,"startTime":"0","endTime":"0","summary":"Curis (CRIS) believes its cash and cash equivalents as of March 31 of $15.0M, together with anticipated gross proceeds of up to an additional $20.2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curis-sees-cash-and-proceeds-enough-for-operations-into-second-half-of-fy27-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curis-sees-cash-and-proceeds-enough-for-operations-into-second-half-of-fy27-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635257392","title":"Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2635257392","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635257392?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:03","pubTimestamp":1778623413,"startTime":"0","endTime":"0","summary":"Impact Therapeutics (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$20.10 per H-share, near the lower end of the of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SPCX","BK4139","BK4539","07630","BK4007","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635022543","title":"Cosciens Biopharma Q1 EPS $2.90 Up From $(1.16) YoY, Sales $1.888M Up From $1.387M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635022543","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635022543?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:59","pubTimestamp":1778623185,"startTime":"0","endTime":"0","summary":"Cosciens Biopharma (OTC:CSCIF) reported quarterly earnings of $2.90 per share. This is a 350 percent increase over losses of $(1.16) per share from the same period last year.  The company reported $1.888 million in sales","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52510616/cosciens-biopharma-q1-eps-2-90-up-from-1-16-yoy-sales-1-888m-up-from-1-387m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Cosciens Biopharma Q1 EPS $2.90 Up From $(1.16) YoY, Sales $1.888M Up From $1.387M YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCIF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225197","title":"BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225197","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225197?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:54","pubTimestamp":1778622867,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52510501/bridgebio-oncology-q1-eps-526-11-down-from-54-230-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","NQmain","NDX","QQQ","QQQJ","MNQmain","FTEC","QQQE","NVIW.SI","QDTE","QQQM","QYLG","IYW","JEPQ","BBOT","QID","QQQA","TQQY","PSQ","QQQY","ONEQ","GPIQ",".IXIC","TECS","SQQQ","TQQQ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225276","title":"Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225276","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225276?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:50","pubTimestamp":1778622605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM) and Kalaris Therapeutics (KLRS) with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immunome-imnm-kalaris-therapeutics-klrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immunome-imnm-kalaris-therapeutics-klrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","IMNM","BK4585","BLSX","XBI","LU0128526141.USD","BK4563","BK4588","KLRS","LABU","BK4112","BLSG","BK4581","BK4139","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635256302","title":"BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635256302","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635256302?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:43","pubTimestamp":1778622212,"startTime":"0","endTime":"0","summary":"BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results May 12 (Reuters) - Damora Therapeutics Inc DMRA.O:DAMORA THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT COR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225653","title":"BRIEF-Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225653","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225653?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:43","pubTimestamp":1778622198,"startTime":"0","endTime":"0","summary":"BRIEF-Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate UpdateMay 12 (Reuters) - iBio Inc IBIO.O:IBIO REPORTS Q3 FISCAL YEAR 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDAT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA6B7PZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBIO","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635255292","title":"Curis Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635255292","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635255292?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:42","pubTimestamp":1778622166,"startTime":"0","endTime":"0","summary":"Curis Inc reports results for the quarter ended March 31 - Earnings SummaryCuris Inc CRIS.OQ reported a quarterly adjusted loss of $1.25 per share for the quarter ended March 31, identical to the same","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P39X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225559","title":"BRIEF-Burzynski Research Institute Inc - Stanislaw R. Burzynski To Cease Funding For SEC Reporting Costs - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225559","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225559?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:40","pubTimestamp":1778622053,"startTime":"0","endTime":"0","summary":"BRIEF-Burzynski Research Institute Inc - Stanislaw R. Burzynski To Cease Funding For SEC Reporting Costs - SEC FilingMay 12  - Burzynski Research Institute Inc BZYR.PK:BURZYNSKI RESEARCH INSTITUTE INC - STANISLAW R. BURZYNSKI TO CEASE FUNDING FOR SEC REPORTING COSTS - SEC FILINGBURZYNSKI RESEARCH INSTITUTE INC - EXPECTS INABILITY TO FILE FY2026 FORM 10-K AND PERIODIC REPORTS - SEC FILINGSource text: [ID:n0001104659-26-059409]Further company coverage: BZYR.PK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BZYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635822536","title":"Kodiak Sciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635822536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635822536?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:35","pubTimestamp":1778621720,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc reports results for the quarter ended March 31 - Earnings SummaryKodiak Sciences Inc KOD.OQ reported a quarterly adjusted loss of 94 cents per share for the quarter ended March 31,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P39K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225549","title":"Achieve Life Sciences files prospectus for resale of shares by holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225549","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225549?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:31","pubTimestamp":1778621468,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences (ACHV) filed a prospectus relating to the resale by selling shareholders, from time to time, of up to 49.42M shares of common...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/achieve-life-sciences-files-prospectus-for-resale-of-shares-by-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/achieve-life-sciences-files-prospectus-for-resale-of-shares-by-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACHV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.0881},{"period":"3month","weight":0.0682},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.31},{"period":"ytd","weight":0.0841}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}